Prevalence of and factors related to the use of antidepressants and benzodiazepines: results from the Singapore Mental Health Study

BMC Psychiatry

Siow Ann Chong¹  Edimansyah Abdin¹  Janhavi A Vaingankar¹  Vincent YF He¹  Mythily Subramaniam² 

[1] Research Division, Institute of Mental Health, Singapore, Singapore;Research Division, Institute of Mental Health, Buangkok Green Medical Park, 10 Buangkok View, Singapore 539747, Singapore

关键词: Survey;    Alcohol use disorder;    Major depressive disorder;    Benzodiazepine;    Antidepressant;   

Others  :  1123962
DOI  :  10.1186/1471-244X-13-231

 received in 2013-01-15, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Background

Prescription and use of antidepressants and benzodiazepines are common in the general population. Prescription of psychotropic drugs is a complex process: patient, physician and healthcare characteristics mediate, interact and influence it. The current study aimed to establish the prevalence and factors associated with the use of antidepressants (ADs) and benzodiazepines (BZDs) in Singapore.

Methods

The Singapore Mental Health Study (SMHS) was a nationally representative survey of Singapore Residents aged 18 years and above. Face-to-face interviews were conducted from December 2009 to December 2010. The diagnoses of mental disorders were established using the Composite International Diagnostic Interview version 3.0 (CIDI-3.0). The pharmacoepidemiology section was used to collect information on medication use.

Results

The overall prevalence estimates for ADs and BZDs use during the 12 months prior to the interview were 1.1% and 1.2% respectively. In all, 2.0% had used ADs and/or BZDs. ‘Help seeking for emotional or mental health problems’ was the most important predictor for the use of ADs and BZDs—help seekers were much more likely to use ADs (adjusted OR: 31.62, 95% CI: 13.36–74.83) and more likely to use BZDs than non-help seekers in the previous 12 months (adjusted OR: 34.38, 95% CI: 12.97–91.16). Only 27.6% of those with 12-month major depressive disorder (MDD) had sought formal medical help for their problems and ADs were being used by just over a quarter of this ‘help-seeking group’ (26.3%).

Conclusions

We found that the use of ADs and BZDs in our population was relatively low, and ‘help-seeking’ was the most important predictor of the use of ADs and BZDs. In concordance with research from other Western countries, use of ADs was low among those with 12-month MDD.

【 授权许可】

   
2013 Subramaniam et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ustün TB, von Korff M: Primary mental health services: access and provision of care. In Mental illness in general health care. Edited by Ustün TB, Sartorius N. Chichester: John Wiley; 1995:347-360.
• [2]Ohayon MM, Caulet M: Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychiatry 1996, 41(7):457-464.
• [3]The ESEMeD⁄MHEDEA 2000 investigators: Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109(suppl 420):55-64.
• [4]Demyttenaere K, Bonnewyn A, Bruffaerts R, De Girolamo G, Gasquet I, Kovess V, Haro JM, Alonso J: Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord 2008, 110(1–2):84-93.
• [5]Kisely S, Linden M, Bellantuono C, Simon G, Jones J: Why are patients prescribed psychotropic drugs by general practitioners? Results of an international study. Psychol Med 2000, 30(5):1217-1225.
• [6]Nielsen MW, Hansen EH, Rasmussen NK: Patterns of psychotropic medicine use and related diseases across educational groups: national cross-sectional survey. Eur J Clin Pharmacol 2004, 60(3):199-204.
• [7]Paulose-Ram R, Jonas BS, Orwig D, Safran MA: Prescription psychotropic medication use among the U.S. Adult population: results from the third national health and nutrition examination survey, 1988–1994. J Clin Epidemiol 2004, 57(3):309-317.
• [8]Grinshpoon A, Marom E, Weizman A, Ponizovsky AM: Psychotropic drug use in Israel: results from the national health survey. Prim Care Companion. J Clin Psychiatry 2007, 9(5):356-363.
• [9]Ohayon MM, Lader MH: Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002, 63(9):817-825.
• [10]Blennow G, Romelsjö A, Leifman H, Leifman A, Karlsson G: Sedatives and hypnotics in Stockholm: social factors and kinds of use. Am J Public Health 1994, 84(2):242-246.
• [11]Magrini N, Vaccheri A, Parma E, D’Alessandro R, Bottoni A, Occhionero M, Montanaro N: Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Eur J Clin Pharmacol 1996, 50(1–2):19-25.
• [12]Mojtabai R: Datapoints: prescription patterns for mood and anxiety disorders in a community sample. Psychiatr Serv 1999, 50(12):1557.
• [13]Bellantuono C, Arreghini E, Adami M, Bodini F, Gastaldo M, Micciolo R: Psychotropic drug prescription in Italy. A survey in general practice. Soc Psychiatry Psychiatr Epidemiol 1989, 24(4):212-218.
• [14]Taggart LAP, Mc Cammon SL, Allred LJ, Horner RD, Harold MJ: Effect of patient and physician gender on prescriptions for psychotropic drugs. J Womens Health 1993, 2(4):353-357.
• [15]Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, et al.: Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109(suppl 420):47-54.
• [16]Chong SA, Abdin E, Sherbourne C, Vaingankar J, Heng D, Yap M, Subramaniam M: Treatment gap in common mental disorders: the Singapore perspective. Epidemiol Psychiatric Sci 2012, 21(2):195-202.
• [17]Uchida N, Chong MY, Tan CH, Nagai H, Tanaka M, Lee MS, Fujii S, Yang SY, Si T, Sim K, Wei H, Ling HY, Nishimura R, Kawaguchi Y, Edwards G, Sartorius N, Shinfuku N: International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. Psychiatry Clin Neurosci 2007, 61(5):522-528.
• [18]Xie F, Tan CH, Li SC: Are they being used safely? A retrospective cross-sectional tertiary health care survey of selective serotonin reuptake inhibitors prescribing practice in Singapore. Hum Psychopharmacol 2005, 20(7):459-465.
• [19]Subramaniam M, Vaingankar J, Heng D, Kwok KW, Lim YW, Yap M, Chong SA: The Singapore mental health study: an overview of the methodology. Inter J Methods Psychiatry 2012, 21(2):149-157.
• [20]Kessler RC, Ustun TB: The world mental health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004, 13:93-121.
• [21]Rush AJ, Carmody T, Relmiz PE: The Inventory of Depressive Symptomatology (IDS). Int J Methods Psychiatr Res 2000, 9:45-59.
• [22]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [23]Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16 item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR). Biol Psychiatry 2003, 54(5):573-583.
• [24]Chong SA, Vaingankar J, Abdin E, Subramaniam M: The prevalence and impact of major depressive disorder among Chinese, Malays and Indians in an Asian multi-racial population. J Affect Disord 2012, 138(1–2):128-136.
• [25]Chong SA, Abdin E, Vaingankar JA, Heng D, Sherbourne C, Yap M, Lim YW, Wong HB, Ghosh-Dastidar B, Kwok KW, Subramaniam M: A population-based survey of mental disorders in Singapore. Ann Acad Med Singapore 2012, 41:49-66.
• [26]Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, et al.: European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109(suppl 420):21-27.
• [27]Hjern A, Wicks S, Dalman C: Social adversity contributes to high morbidity in psychoses in immigrants – a national cohort study in two generations of Swedish residents. Psychol Med 2004, 34(6):1025-1033.
• [28]Morgan C, Burns T, Fitzpatrick R, Pinforld V, Priebe S: Social exclusion and mental health: conceptual and methodological review. Br J Psychiatry 2007, 191:477-483.
• [29]Demyttenaere K, Ansseau M, Constant E, Albert A, Van Gassen G, van Heeringen K: Do general practitioners and psychiatrists agree about defining cure from depression? The DEsCRIBE™ survey. BMC Psychiatry 2011, 11:169. BioMed Central Full Text
• [30]Mendlewicz J: Optimising antidepressant use in clinical practice: towards criteria for antidepressant selection. Br J Psychiatry Suppl 2001, 42:S1-S3.
• [31]Chua HC, Chan LL, Chee KS, Chen YH, Chin SA, Chua PL, Fones SL, Fung D, Khoo CL, Kwek SK, Lim EC, Ling J, Poh P, Sim K, Tan BL, Tan CH, Tan LL, Tan YH, Tay WK, Yeo C, Su HC, Singapore Ministry of Health: Ministry of health clinical practice guidelines: depression. Singapore Med J 2012, 53(2):137-143.
• [32]Subramaniam M, Abdin E, Vaingankar J, Chong SA: Prevalence, correlates, comorbidity and severity of bipolar disorder: results from the Singapore mental health study. J Affect Disord 2013, 146(2):189-196.
• [33]Wittchen HU, Lieb R, Wunderlich U, Schuster P: Comorbidity in primary care: presentation and consequences. J Clin Psychiatry 1999, 60(suppl 7):29-36.
• [34]Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Bégaud B, Verdoux H, Moore N: Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004, 60(7):523-529.
• [35]Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV: Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. J Affect Disord 2009, 117(suppl 1):S1-S2.
• [36]American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder, third edition. Washington DC: Arlington (VA); 2010:152.
• [37]Davidson JR, Zhang W, Connor KM, Ji J, Jobson K, Lecrubier Y, McFarlane AC, Newport DJ, Nutt DJ, Osser DN, Stein DJ, Stowe ZN, Tajima O, Versiani M: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). J Psychopharmacol 2010, 24(1):3-26.
• [38]Ashley MJ, le Riche WH, Hatcher J, Kornaczewski A, Schmidt W, Rankin JG: ‘Mixed’ (Drug abusing) and ‘pure’ alcoholics: a socio-medical comparison. Br J Addict 1978, 73(1):19-34.
• [39]Busto U, Simpkins J, Sellers EM, Sisson B, Segal R: Objective determination of benzodiazepine use and abuse in alcoholics. Br J Addic 1983, 78(4):429-435.
• [40]Ross HE: Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics. Addiction 1993, 88(2):209-218.
• [41]Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: Substance abuse treatment admissions for abuse of benzodiazepines. Rockville, MD: The TEDS Report; 2011.
• [42]Haukka J, Suvisaari J, Tuulio-Henriksson A, Lönnqvist J: High concordance between self-reported medication and official prescription database information. Eur J Clin Pharmacol 2007, 63(11):1069-1074.